Navigating Contradictions: Insights from the Latest NewCo Earnings Call on Valuation, OEM Impact, and Market Dynamics
Tuesday, May 6, 2025 7:34 pm ET
2min read None
Revenue and Earnings Performance:
- Teleflex reported revenues of $700.7 million for Q1 2025, down 5% year-over-year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis.
- The decline was primarily due to softer-than-expected orders in EMEA and the impact of volume-based procurement in China.
Geographic Segment Revenues:
- Americas revenues were $475.7 million, down 3.2% year-over-year, impacted by OEM declines and challenges in the UroLift office sites of service.
- EMEA revenues decreased 2.8% year-over-year, primarily offset by strong performance in Surgical and Vascular Access but affected by lower-than-expected orders at the end of the quarter.
Impact of Tariffs:
- Teleflex anticipates a $55 million impact from tariffs enacted since the issuance of their previous guidance for the full year 2025.
- The impact will be recorded in cost of goods sold, with approximately 50% associated with China and 35% with Mexico.
Product Category Growth:
- Vascular Access revenues increased 1.9% year-over-year, driven by double-digit growth in PICCs and solid performance in EZ-IO, despite a decline in OEM revenue.
- Interventional Urology reported a 10.7% decrease in year-over-year revenues, pressured by UroLift, particularly in the office sites of service, while Barrigel delivered strong double-digit growth.
Revenue and Earnings Performance:
- Teleflex reported revenues of $700.7 million for Q1 2025, down 5% year-over-year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis.
- The decline was primarily due to softer-than-expected orders in EMEA and the impact of volume-based procurement in China.
Geographic Segment Revenues:
- Americas revenues were $475.7 million, down 3.2% year-over-year, impacted by OEM declines and challenges in the UroLift office sites of service.
- EMEA revenues decreased 2.8% year-over-year, primarily offset by strong performance in Surgical and Vascular Access but affected by lower-than-expected orders at the end of the quarter.
Impact of Tariffs:
- Teleflex anticipates a $55 million impact from tariffs enacted since the issuance of their previous guidance for the full year 2025.
- The impact will be recorded in cost of goods sold, with approximately 50% associated with China and 35% with Mexico.
Product Category Growth:
- Vascular Access revenues increased 1.9% year-over-year, driven by double-digit growth in PICCs and solid performance in EZ-IO, despite a decline in OEM revenue.
- Interventional Urology reported a 10.7% decrease in year-over-year revenues, pressured by UroLift, particularly in the office sites of service, while Barrigel delivered strong double-digit growth.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
_442a2dcc1749832873286.jpeg)
_e68fac6d1749831664430.jpeg)
